A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

Summary

This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL). This clinical trial uses a drug called PF-08046044/SGN-35C . The study drug is in testing and has not been approved for sale. This is the first time SGN -35C will be used in people. This study will test the safety of SGN-35C in participants with lymphoma. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have three parts. Parts A and B of the study will find out the best dose and dosing schedule for SGN-35C. Part C will use the dose found in parts A and B to find out how safe SGN-35C is and if it works to treat select lymphomas.

Timeline

Start

2024-05-28

Primary completion

2026-04-13

Completion

2026-04-13

Outcome

Outcome not reported

Stopped (Business): “The trial was terminated for strategic reasons due to portfolio reprioritization. The decision was not based on any safety or regulatory concerns”

Drugs

Indications